USNANYSEMedicinal Chemicals & Botanical ProductsFiscal year ends January 3

USANA HEALTH SCIENCES INC

Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 13, 2026

$14.89−0.65 (-4.18%)

Close on Oct 19, 2026

Market cap: $275.26M
P/E (TTM): –
Dividend yield: –

USANA HEALTH SCIENCES INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2026-01-03	FY 2024 2024-12-28	FY 2023 2023-12-30	FY 2022 2022-12-31	FY 2021 2022-01-01	FY 2020 2021-01-02	FY 2019 2019-12-28	FY 2018 2018-12-29	FY 2017 2017-12-30	FY 2016 2016-12-31	FY 2015 2016-01-02	FY 2014 2015-01-03	FY 2013 2013-12-28	FY 2012 2012-12-29	FY 2011 2011-12-31	FY 2010 2011-01-01	FY 2009 2010-01-02
Revenue	925	855	921	999	1,186	1,135	1,061	1,189	1,047	1,006	918	790	718	649	582	518	437
Cost of Revenue	201	161	177	194	218	209	188	201	179	180	160	141	127	116	102	95	90
Gross Profit	724	693	744	805	969	926	873	989	868	826	759	650	591	533	480	422	347
Research & Development	11	12	11	12	11	11	10	10	8.95	8.84	6.42	5.13	5.08	4.66	4.07	3.84	–
Selling, General & Admin	337	263	257	262	279	261	268	275	265	234	209	185	166	154	137	121	100
Advertising Expenses	43	4.97	4.76	5.05	12	9.85	12	10	12	12	14	4.94	3.65	3.94	3.89	1.20	–
Operating Expenses	687	627	651	697	798	749	727	800	735	687	617	534	474	435	403	354	296
Operating Income	37	66	93	108	170	176	146	188	133	139	142	116	117	98	77	68	51
Interest Expense	0.84	0.28	0.26	0.19	0.06	0.51	0.07	0.04	0.05	0.44	0.02	0.13	0.00	0.02	0.01	0.09	0.61
Interest & Investment Income	2.42	11	9.64	3.79	2.52	2.54	4.71	4.43	2.19	1.48	1.12	0.50	0.46	0.25	0.19	0.17	0.08
Other Non-Operating Income	4.10	10	9.38	1.01	0.45	1.46	4.31	3.16	2.14	-0.07	0.93	-0.45	-0.13	0.25	0.22	0.65	0.19
Merger & Restructuring Charges	6.46	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	6.97	0	0	0	0	0	0	0	2.73	0	0	0	0	0	0	–	–
Gain (Loss) on Sale of Assets	2.09	0.00	-0.01	-0.14	-0.06	-0.19	-0.08	-1.81	-0.02	-0.12	0.00	-0.05	0.02	0.04	-0.05	-0.09	0.15
Pretax Income	42	76	102	109	171	178	150	192	135	139	143	116	117	98	77	69	51
Income Tax Expense	30	34	39	39	54	53	50	65	72	39	48	39	38	32	27	23	17
Net Income incl. Noncontrolling Interests	11	42	64	69	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	11	42	64	69	117	125	101	126	63	100	95	77	79	66	51	46	34
Net Income to Common	–	–	64	69	117	125	101	126	63	100	95	77	79	66	51	46	–
EPS (Basic)(per share)	0.58	2.20	3.31	3.60	5.78	5.89	4.44	5.24	2.57	4.14	3.72	2.90	2.89	2.29	1.65	1.47	1.10
EPS (Diluted)(per share)	0.58	2.19	3.30	3.59	5.73	5.86	4.41	5.12	2.53	3.99	3.59	2.80	2.78	2.23	1.63	1.43	1.09
Shares Outstanding (Basic, Weighted)(shares)	19	19	19	19	20	21	23	24	24	24	25	26	27	29	31	31	31
Shares Outstanding (Diluted, Weighted)(shares)	19	19	19	19	20	21	23	25	25	25	26	27	28	30	31	32	31
EBITDA	70	81	106	121	183	190	161	205	149	152	152	125	126	107	86	76	58

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 4, 2026

Profitability, TTM

Gross margin: 77.4%
Operating margin: -0.1%
Net margin: -2.4%
Return on equity, FY2025: 2.0%

Financial strength

Current ratio: 2.66
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 159.5%

Valuation

P/E ratio: –
Price to sales: 0.30
Price to book: 0.52
Dividend yield: –